Health Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)

Similar documents
How best to structure a laboratory network with new technologies

When good genes go bad

Xpert MTB/RIF Training. Indira Soundiram 2012

DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?

Ken Jost, BA, has the following disclosures to make:

POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

HIV Clinicians Society Conference TB/HIV Treatment Cascade

Progress Report March 2016

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

<<Insert Laboratory Logo if applicable>> LABORATORY MANUAL MYCOBACTERIOLOGY CLINICAL SITE

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

TB Laboratory for Nurses

TB 101 Disease, Clinical Assessment and Lab Testing

Kritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen

National Xpert MTB/RIF Programme

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

Receipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

TB Intensive San Antonio, Texas November 11 14, 2014

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Diagnosis of drug resistant TB

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis

The Lancet Infectious Diseases

New frontiers: Innovation and Access

CULTURE OR PCR WHAT IS

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China

Report on WHO Policy Statements

Principles of laboratory diagnosis of M. tuberculosis. Anne-Marie Demers, MD, FRCPC 11 September 2017

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

INTENSIFIED TB CASE FINDING

Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

New Standards for an Old Disease:

Ministry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)

A retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

Diagnosis of tuberculosis in children

Nucleic Acid Amplification Testing for the Diagnosis of TB

GeneXpert (Xpert MTB/RIF): what is the future?

TOG The Way Forward

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation

TB: A Supplement to GP CLINICS

Evaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC Saye-Zaria Nigeria

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

Progress Report July 2014

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

Assessing the programmatic management of drug-resistant TB

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Xpert MTB/RIF assay validation experience --- impact and plan in China

Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives

Supplementary appendix

7. Are you currently engaged in research that could support new TB diagnostic assay development? Yes No

Identify, Evaluate, and Treat! Steps to Improve TB Contact Investigation in the Pacific November 27 30, 2018

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance:

TB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017

TB is Local. Barry Chin, Boston Globe, 10/15/2008. * BUT only in appropriate setting

SA TB Guidelines The interface with Advanced Clinical Care

Challenges in Capacity in SA for diagnosing DR-TB

Online Annexes (2-4)

Diagnosis of HIV-Associated Tuberculosis

Planning for the implementation of new diagnostic tests

PCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital,

Objectives. TB Laboratory Methods

2018 Tuberculosis Clinical Intensive: Infection Prevention & Control. > No disclosures

Report of TB/HIV Diagnostics Task Force. Barbara Laughon NIAID, NIH

Towards Harmonization of Mycobacteriology in TB Trials. Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures

WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears

Role of Xpert MTB/RIF Assay in the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance

TB infection control: overview and importance

Laboratory Diagnostic Techniques. Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust

General Session IV - Dale Schwab April 20, 2017

Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine

Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10

Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service

Molecular assays in Tuberculosis. Jatin Yegurla Junior resident

MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

Update on Management of

Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Revised National Tuberculosis Control Programme

Detection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India

Heather Alexander, PhD

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

Introduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24

Management of Tuberculosis Training for Health Facility Staff SECOND EDITION. B. Detect Cases of TB

Transcription:

Health Care Worker Training on Roll Out New TB Diagnostic Test Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)

Overview Specimen Collection Investigations to request Sorting & registering specimens New Diagnostics o GeneXpert NHLS Reports o Fax Lists o Hard Copies o www.disa o Telephonic Ordering Diagnostic tests used by NHLS o Microscopy o Culture o Differential o DST o Hain (LPA)

Why are we using GeneXpert now? WHO Recommendation (2010) and NSP WHO Strong Recommendation: The new automated DNA test for TB should be used as the initial diagnostic test in individuals suspected of MDR-TB or HIV/TB (i.e. Most TB suspects in SA) Pillars of SA National Strategic Plan: (2012-2017 draft) Universal testing for HIV and screening for TB the primary objectives being to ensure that all citizens know their HIV and TB status, and to prevent new HIV and TB infections Health and wellness the primary objective being to ensure access to quality treatment, care and support services for those with HIV and/or TB and to develop programmes to focus on wellness Slide courtesy of Prof Wendy Stevens

Advantages and limitations Advantages Decreased turn around time to reduce the diagnostic delay Increased sensitivity and specificity Only detects Mycobacterium tuberculosis complex Can be used in children who can cough (induced sputum) Can be used by non-laboratory staff

Disadvantages Disadvantages Cannot be used for monitoring Only detects rifampicin resistance Qualitative result Copyright NHLS 2003 Slide 5

Specimen Collection NOTE: Quality of the result is ONLY as good as the quality of the specimen received

Sputum Collection Use external sputum booths (where available) to collect specimens - if no booth suggest outside building Make sure no other patients are present Always stand BEHIND the patient EXPLAIN the steps to the patient and make sure the patient understands: o Ask the patient to rinse mouth with water o Advise patient to be careful & direct sputum into container so as not to contaminate outside of container o Give the patient LABELLED container without the lid o If the patient does not cough spontaneously, ask the patient to take several deep breaths and then hold their breath o Seal sputum jar properly after specimen produced

Closing sputum container Check contents sputum jar Need at least 5ml sputum per jar Tighten cap of sputum jar to make sure it does not leak Place sputum jar into plastic bag obtainable from the NHLS

What investigations to request on TB Suspects ALL TB suspects to have 2 spot sputum specimens taken ONE hour apart Previously requested: o New: direct x2 o Retreatment: direct x2 & x1 culture and DST o HCW s, prisoners, contacts DR-TB patients: direct x2 & x1 culture and DST Now request GeneXpert

Extrapulmonary samples Circular H13-2013 - Restriction of Genexpert test requests on specimens other than Sputa and Tracheal Aspirate.pdf Copyright NHLS 2003 Slide 10

Sputum Request Form Complete the request forms properly Use (PreHmis) PHC patient stickers on sputum jar and on NHLS request form Fold the request form with the patients details facing outward Insert the sample into the correct sleeve of NHLS specimen bag Insert the form into the other sleeve

1. Name facility 2. Patient Details (patient sticker) 3. Tests requested MUST add HIV status under remarks (HIV +ve/hivve/hiv unknown) and write GeneXpert 4. Specimen collection details Copyright NHLS 2003 Slide 12

Preparation for dispatch sputum specimens to NHLS The TWO plastic bags must be stapled together at the top (each bag contains 1 specimen & 1 request form) Both specimens (stapled together) must be sent to NHLS together and preferably should be sent to NHLS on the same day If it cannot be sent on the same day, keep refrigerated (if no fridge available keep in a cool dark place)

Samples stapled together

NHLS Sputum Request Form KMBT25020111011084651.pdf Copyright NHLS 2003 Slide 15

Sorting and Registering Specimens at NHLS On receipt of sputum samples NHLS sorts & registers each specimen received on database BEFORE dispatching to each section for testing. NOTE each specimen has its own unique registration number - each lab has own code (SGT XXXX or SWO XXXX) Leaking specimens are registered BUT discarded report sent to clinic specimen leaked, please repeat

Each specimen receives a unique registration number i.e. SGT Information from sputum request form used to register each specimen according to whether suspect/case & TB history i.e. new/rerx

TB Suspects Always 0 months New suspect = SPN0 Retreatment suspect = SPR0 Each specimen receives a unique registration number i.e. SGT Information from sputum request form used to register each specimen according to whether suspect/case & TB history i.e. new/rerx Confirmed Drug Sensitive TB Case Conversion sputum done at 7 weeks or 11 weeks New TB case conversion = SPN2 Retreatment TB case conversion = SPR2 Discharge sputum done at 5 months or 7 months New TB case discharge = SPN5 Retreatment TB case discharge = SPR5 Other Please note if no time stated New = SPUN Retreatment = SPUR If it is NOT indicated if a suspect or a case and/or new or retreatment will be registered as SPU Confirmed Drug Resistant TB Case Monthly sputum sample sent on all drug resistant TB cases (MDR and/or XDR) for smear and culture will be registered as SPMDR

What TB diagnostic tests are used by NHLS? Diagnostic Tests Direct (microscopy) Culture (MGIT) Drug Sensitivity Testing Line Probe Assay (Hain) New Diagnostic Tests GeneXpert

New Diagnostic Test

Why the need for new diagnostics? Need tests to confirm diagnosis in sm- TB & drug resistance much sooner to be able to start treatment sooner Direct not very sensitive Culture takes up to 5 weeks

MTB/RIF cartridge and GXP 4

GeneXpert Technology Xpert MTB/RIF Assay GX1 GX2 GX4 GX16 GeneXpert Infinity 80 4 8 16 64 320 throughput/8 hr day

What is GeneXpert (GXP) The GXP is a platform for the Xpert MTB/Rif cartridge-based fully automated nucleic acid amplification test for TB case detection and rifampicin resistance Designed to extract, amplify and identify targeted 6110 and rpob nucleic acid sequences Note - additional tests cannot be ordered after GXP has been done

Which samples get GXP? ALL TB suspects one sputum specimen will have genexpert (includes new; ReRx; MDR contacts; HCWs & prisoners) Only 1 GXP test will be done per patient GeneXpert CANNOT be used for follow-up specimens on patients with confirmed TB on treatment need to follow Palsa Plus i.e. & send either smear or culture for conversion & discharge monitoring

What are the benefits of GeneXpert? GeneXpert more sensitive To see AFBs on smear needs 10,000 bacilli per ml GeneXpert only needs 150 bacilli per ml Copyright NHLS 2003 Slide 28

What are the benefits of GeneXpert? GXP has specificity of 99.2% Detects 70% sm-ve Useful in the diagnosis of TB in HIV co-infected patients Has an instrument turnaround time of 2 hours results will be back at facility within 24 hours Easy to use

How to interpret GeneXpert results & what to do?

Copyright NHLS 2003 Slide 31

GeneXpert +ve and Rifampicin Sensitive 2 GXP MTBCD Pos Rif S.pdf

GeneXpert +ve Rifampicin Sensitive On receipt of GeneXpert result Start TB treatment do NOT wait for sm result When sm result received register as either sm+ve OR sm-ve Follow-up at conversion or discharge as per Palsa Plus for sm+ve or sm-ve

Copyright NHLS 2003 Slide 34

GeneXpert Positive & Rifampicin Resistant 3 MTBCD Rif R.pdf

GeneXpert +ve Rifampicin Resistant On receipt GeneXpert result Recall patient for review by PHC MO MO to prescribe MDR treatment with additional INH When cul & DST received MO to review treatment & STOP INH Register patients in DR-TB register

Copyright NHLS 2003 Slide 37

Rif inconclusive.pdf

GeneXpert +ve Rifampicin Inconclusive On receipt GeneXpert result Start drug sensitive TB treatment do NOT wait for sm, culture & DST result When culture & DST result received as RESISTANT stop DS TB treatment & start DR TB treatment When culture & DST result received as SENSITIVE continue DS TB treatment Register as per sm & cul results Copyright NHLS 2003 Slide 39

Copyright NHLS 2003 Slide 40

GeneXpert Neg.pdf Please note the HIV status Copyright NHLS 2003 Slide 41

GeneXpert Negative If HIV+ve NHLS will use 2 nd specimen to do culture & DST On receipt GeneXpert result - manage HIV+ve and HIV-ve as per Palsa Plus

Copyright NHLS 2003 Slide 43

GXP unsuccesful.pdf

GeneXpert Unsuccessful On receipt GeneXpert result If 2 nd GeneXpert unsuccessful take 3 rd specimen for microscopy, culture & DST

GeneXpert Fax List NHLS will send out SEPARATE fax list to clinic with genexpert results GeneXpert results will NOT be included on general fax list

printer alignment.pdf Copyright NHLS 2003 Slide 47

Hard Copy

TB Suspect Register GeneXpert TB Suspect Register.xls Copyright NHLS 2003 Slide 49

Registration GeneXpert Results Record GeneXpert result in blue TB patient folder as well as any other results i.e. sm/cul Record GeneXpert result in TB register as well as any other results i.e. sm/cul Record as GX+ve/GX-ve

Blue TB Folder Pretreatment 2 months 3 months 5/7 months Culture Resistance Sm Date Sm Result Sm Date Sm Result Sm Date Sm Result Sm Date Sm Result Specimen Date Culture result 3/10/11 GX+ve Yes S DST Done R H Z E S 3/10/11 P+++ Remember follow Palsa Plus MUST have a pretreatment smear result for ALL patients tested Gx +ve ALL patients who are sm+ve pretreatment will need to have smears done at 7/11 weeks & 5/7 months ALL patients who are sm-ve pretreatment will NOT have any further sputums sent will be managed clinically for duration treatment

Turn Around Time ( TAT ) NTCP expects the laboratory to adhere to a 24 to 48 hour TAT for sputum microscopy TAT is calculated from the date the specimen is taken until the result is received at the clinic Smears on cultures take longer GeneXpert results will be available in 24 hours

Copyright NHLS 2003 Slide 53

NHLS Reports Copyright NHLS 2003 Slide 54

How does a clinic receive results? Fax lists Hard copy of results sent by post or brought to the clinic by the NHLS courier SMS printers https://wwdisa.nhls.ac.za/start Telephonic report Copyright NHLS 2003 Slide 55

GeneXpert Fax list.pdf Copyright NHLS 2003 Slide 56

Explanation of GXP Fax List GXTB PCR MTBCD Mycobacterium Tuberculosis Detected MTBCN Mycobacterium Tuberculosis NOT Detected GXRIF Rifampicin RIFS Susceptible RIFR RIFZ Resistant Inconclusive Common LEAK Specimen leaked in transit. Please repeat EMTY OSPEC NSMR Received Empty No specimen received No Smear requested

SMS result sms printout.pdf Copyright NHLS 2003 Slide 58

Auramine Fax Lists Copyright NHLS 2003 Slide 59

Explanation of Fax List Copyright NHLS 2003 Slide 60

Ordering stores from NHLS material order form.pdf Copyright NHLS 2003 Slide 61

ww.disa Before calling the lab please check: https://wwdisa.nhls.ac.za/start Copyright NHLS 2003 Slide 62

In summary.. Submit 2 samples together for each suspect GXP simultaneously detects TB and Rifampicin R or S NHLS uses 2 nd sample for further testing Test ordered now shows GeneXP TB Use ww.disa for result lookup

Questions????? Copyright NHLS 2003 Slide 64

Other Diagnostic Tests

Microscopy Directs Microscopy (smear) Copyright NHLS 2003 Slide 66

What is microscopy? Also known as direct Two methods of staining specimens o Ziel-Neelsen o Fluorescent auramine staining Dead bacilli on slide AFBs counted under microscope number bacilli (AFB s) reflect infectivity Useful for monotoring diagnosis of smear +ve TB & identifies most infectious cases Copyright NHLS 2003 Slide 67

Quantitative Reporting of Microscopy Copyright NHLS 2003 Slide 68

Auramine neg 1 Auramine neg.pdf Copyright NHLS 2003 Slide 69

Auramine pos 2 Auramine Pos.pdf Copyright NHLS 2003 Slide 70

Cultures Cultures MGIT Copyright NHLS 2003 Slide 71

What is culture? Specimen processing Liquid culture medium used MGIT automated non-radiometric system uses fluorometric technology Bacilli detected within 7-35 days Much more sensitive than direct Need to confirm bacilli are MTB therefore need to do differential Copyright NHLS 2003 Slide 72

Differential Differential confirms if Mycobacterium TB MPT64 Antigens If no sensitivities requested Copyright NHLS 2003 Slide 73

MOTT.pdf

pos cul with diff.pdf

Drug Susceptibility Testing Susceptibility tests are used to determine susceptibility or resistance of bacillary strain to different TB drugs Three types of susceptibility tests o LPA for first line susceptibility test o Phenotypic susceptibility tests for others o Additional requests MGIT susceptibilty tests referred to Jhb Copyright NHLS 2003 Slide 76

TB Sensitivities Copyright NHLS 2003 Slide 77

What is Hain (Line Probe Assay) The LPA is a molecular diagnostic tool which utilises mycobacterial DNA to identify MTB. Confirms presence or absence of TB Tests first line sensitivities. Not done directly on smear neg samples. Done directly on smear pos suspects not follow up specimens. Follow up specimens: LPA done from MGIT culture. Copyright NHLS 2003 Slide 78

Hain (Line Probe Assay) Copyright NHLS 2003 Slide 79

Line Probe Assay

Direct +ve, PCR MTB +ve (Rif R INH R) 3 PCR pos Rif R INH R.pdf Copyright NHLS 2003 Slide 81

Drug Susceptibility Testing Phenotypic Susceptibility Tests Second Line DST Middlebrooks (7H11) Copyright NHLS 2003 Slide 82

conventional cul diff sens.pdf

Direct +ve PCR MTB +ve (Rif R INH S) 3 PCR pos Rif R INH S.pdf Rif Mono resistance Copyright NHLS 2003 Slide 84

LPA 2 neg.pdf

LPA 1 neg.pdf